STERIS (NYSE:STE) Releases FY 2026 Earnings Guidance

STERIS (NYSE:STE) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 10.150-10.300 for the period, compared to the consensus EPS estimate of 10.220. The company issued revenue guidance of $5.9 billion-$6.0 billion, compared to the consensus revenue estimate of $5.9 billion.

STERIS Stock Up 1.1%

STERIS stock traded up $2.81 during mid-day trading on Wednesday, hitting $264.48. 852,757 shares of the company’s stock were exchanged, compared to its average volume of 470,158. STERIS has a 1-year low of $204.90 and a 1-year high of $269.44. The stock has a 50 day moving average of $259.17 and a two-hundred day moving average of $249.54. The stock has a market cap of $25.96 billion, a P/E ratio of 26.51 and a beta of 1.03. The company has a current ratio of 2.37, a quick ratio of 1.63 and a debt-to-equity ratio of 0.27.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, hitting the consensus estimate of $2.53. STERIS had a return on equity of 14.43% and a net margin of 12.07%.During the same quarter in the previous year, the firm posted $2.32 earnings per share. The firm’s revenue was up 9.2% compared to the same quarter last year. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, analysts anticipate that STERIS will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. STERIS’s dividend payout ratio is presently 36.21%.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, STERIS currently has an average rating of “Moderate Buy” and an average target price of $275.20.

Insiders Place Their Bets

In other STERIS news, VP Renato Tamaro sold 5,036 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the sale, the vice president owned 5,695 shares in the company, valued at $1,466,747.25. This represents a 46.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP John Adam Zangerle sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the sale, the vice president owned 33,669 shares of the company’s stock, valued at $8,926,998.66. This trade represents a 30.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 25,044 shares of company stock valued at $6,586,218. 1.07% of the stock is currently owned by corporate insiders.

Institutional Trading of STERIS

A number of hedge funds have recently made changes to their positions in STE. Geneos Wealth Management Inc. grew its stake in STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the period. Advisory Services Network LLC purchased a new stake in STERIS during the third quarter worth about $68,000. MUFG Securities EMEA plc purchased a new stake in STERIS during the second quarter valued at about $69,000. Brown Brothers Harriman & Co. raised its stake in shares of STERIS by 51.3% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 528 shares of the medical equipment provider’s stock valued at $131,000 after purchasing an additional 179 shares during the period. Finally, Peapack Gladstone Financial Corp bought a new stake in STERIS during the second quarter valued at $200,000. 94.69% of the stock is owned by institutional investors and hedge funds.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.